Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.
The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision.
But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid.
Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal.
Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal.
'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added.
Moderna did not immediately respond to a request for comment.
Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic.
The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna COVID-19 vaccine patents were invalid, and elsewhere.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Manchester's housing crisis is not the council's fault
Andy Burnham frequently says Greater Manchester's teenagers 'can see the skyscrapers from their bedroom window' but can't see 'a path' there. It's a comment he uses to argue for improved education so teenagers can secure a well-paying job in the city centre. But it could just as easily be applied to house prices. Since Mr Burnham took the mayoralty in 2017, thousands of luxury apartments have been constructed in town. Despite traditional economic logic dictating extra supply will lower prices, a council report last year found new 'homes are increasingly priced towards the top of the market however… this can result in the perverse impact of new supply ostensibly adding to the inflationary pressures in parts of the city where new development has been most intense'. READ MORE: Murder arrest at Manchester Airport after death of teen stabbed in car park READ MORE: The 'forgotten' Greater Manchester estate where people are demanding change The average house price in Manchester city centre in April was £270,036. That's more than eight times the average Manchester salary, calculated at £32,704 last November. In the same month, the average rent in the borough of Manchester was listed at £1,310 per month. That's means someone earning the average Manchester salary would have to spend more than half of their take-home pay on rent if they lived alone. Never miss a story with the MEN's daily Catch Up newsletter - get it in your inbox by signing up here But it's not like the council hasn't tried to stop house prices climbing in town. Since 2012, it's had a policy that says a fifth of all units need to be affordable, if a developer is set to make 20 per cent profit. How much money a developer will make is scrutinised by an independent expert, and if they tell the council the 'viability assessment' shows returns under 20 per cent, the developer is exempt from affordable housing. Often, the town hall will still ask developers to make a smaller 'section 106 contribution' to community infrastructure, like schools or parks, or the council's 'housing affordability fund' in lieu of the affordable homes. It also includes 'clawback clauses' when giving out planning permission, so if a developer that initially is exempt from affordable housing then makes more than 20 per cent profit, the council can get more cash out of them. While they rarely produce big returns to the public purse, it was recently revealed one had to pay £700,000 for a city centre project. How much developers chip into public projects and affordable housing made headline news this summer, following a court case between Mr Burnham's office, the Greater Manchester Combined Authority (GMCA) and Aubrey Weis, a major city centre landowner. Mr Weis claimed the GMCA's decision to loan major developer Renaker £140m 'distorted' the property market. The Competition Appeals Tribunal dismissed the claim. Contributions were raised again by opposition Lib Dem councillor Chris Northwood earlier this month, who told the town hall: 'Many, many large-scale developments in the city centre are approved through planning with zero affordable housing. 'That means we are not building those mixed, integrated communities for the future we want. It seems to me the existing system of independent assessments does not produce meaningful figures… and there's a huge lack of transparency over these.' Her motion referenced a 2017 Shelter report which found developers 'inflate their bids for land', pushing up the total bill for a building. That means profit margins take a hit in viability assessments so they don't hit the 20 per cent threshold and don't build affordable units, the report said. 'Developers know that they can use the loophole, and so factor it into their bids for new sites,' author Rose Grayston concluded. 'In fact, they must: if one developer does not plan to use the loophole, they risk being outbid for land by another one who does. This pushes the price of land up, making development more expensive.' Coun Northwood's motion was amended by governing Labour councillors, who point out most affordable housing is actually funded by a completely different scheme. Last year, 3,864 new homes were built in Manchester, with around 3,300 available on the open market, and 511 affordable (13 per cent of the total). More is coming — contractors are currently building roughly 12,000 homes in the city, 1,470 of which are affordable (12 per cent), and about 18,500 units are in the planning system now, with around 2,250 affordable (12 per cent). In fact, section 106 money only builds about one in 10 affordable homes in Manchester. The other 90 per cent is funded by grants given to housing associations and public bodies, largely from Homes England and the GMCA. That's why town hall chiefs have been genuinely encouraged by Rachel Reeves' decision to 'double the grant pot' to £39b over the next decade, because it's a model they understand. And it's a game they've become good at playing. Recently, One Manchester finished 24 new apartments and houses on Brigham Street in Openshaw, made possible by Homes England grants which created Manchester council's £3m 'Project 500' initiative, that helps housing associations cover the cost of building on brownfield land. All 24 homes are affordable, as are all Project 500 homes — 90 per cent will also be available at social rent. Grants also help the authority's own development company, called This City, which recently finished No. 1 Ancoats Green, a 129-apartment and townhouse development where 30 per cent are available at 'Manchester Living Rent', set at the level of the local housing allowance. Another city centre project from housing association Great Places will create 89 affordable flats on Laystall Street in the Northern Quarter in spring 2026 — again made possible by grant funding. The council has other levers to help get affordable homes to Mancs. A fifth of the massive, 850-home development planned for Mayfield will be affordable, partly due to the fact the town hall is a member of the 'partnership' overseeing the redevelopment of the area into a new neighbourhood. It's also been able to lean on developer Salboy to make nearly 30 per cent of the homes in its Viadux 2 project affordable, because it owns the land where two towers will shoot up. A new council initiative has also brought 276 empty homes back to the market, although only three have gone towards social housing. But while efforts are being made to solve Manchester's housing crisis, the current rate of building is clearly not enough. A recent town hall report found the number of people on the top three bands of the council's housing register surged to 11,500, an increase of 15 per cent, last year. It's grown by 49 per cent since April 2022. In part, the reason why affordable housing demand is growing when affordable housing supply is increasing is because newbuild figures are tempered by right-to-buy sales. Council tenants can purchase their home after three years. Last year, 137 did so, so the 'net gain' of affordable housing to Manchester wasn't 511 — it was 374. Over the last decade, the city built 3,998 affordable homes. It lost 2,139 to right-to-buy, so a net rise of only 1,859. The government is planning on making it harder for council tenants to buy their homes, extending the minimum occupancy window to 10 years and exempting any new stock from right-to-buy for 35 years — so the problem will subside, but not disappear. It's not just smaller gains that's an issue. Roughly half of all newly-constructed city centre homes, which would be perfect for first-time-buyers, are bought by investors to rent out — something council officer Nick Cole called 'a concern', because it cuts the amount of homes available to buy and increases the number of renters, blocking up the market. Nationally, big changes are in store for renters, as section 21 'no fault evictions' are expected to be abolished in early 2026 by the government. Ahead of the move, the council is seeing a spike in section 21 notices, sometimes following persistent increases in rent to a point where tenants can make ends meet — so they enter the council housing system. The question of how many affordable homes and who should pay for them looms as Manchester council is preparing its first local plan for 13 years — effectively its blueprint for development. It will be formally adopted by the end of the year. Campaigners are calling for all new developments to include 30 per cent affordable housing, but the final details of the plan have yet to be released. Whatever the final document says in the autumn, Manchester as a city will need to keep building affordable homes — and that requires grants to fund it, the council to steer it, and developers to play their part.
Yahoo
7 minutes ago
- Yahoo
The most expensive transfers of the summer 💸
Liverpool in total domination. July has just ended, time to take a look at the most expensive transfers of the summer so far. Liverpool has the two most expensive transfers of this market. Florian Wirtz and Hugo Ekitike cost over €200M together. In the top 5, we find only one club outside the Premier League: Galatasaray with the official arrival of Victor Osimhen (€75M). A transfer tied with that of Bryan Mbeumo to Manchester United. The Red Devils are also closing the deal with the arrival of Matheus Cunha. Which of these recruits are you most looking forward to seeing play this season? Give us your opinion in the comments! This article was translated into English by Artificial Intelligence. You can read the original version in 🇫🇷 here. 📸 Alex Grimm - 2025 Getty Images
Yahoo
16 minutes ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
